INSTITUTO BUTANTAN - ADALIMUMABE

Aperçu du produit

About INSTITUTO BUTANTAN - ADALIMUMABE

INSTITUTO BUTANTAN - ADALIMUMABE is a medication containing the active ingredient Adalimumab, classified as Tumor Necrosis Factor Blocker. Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Adalimumab, the active ingredient in INSTITUTO BUTANTAN - ADALIMUMABE, belongs to the Tumor Necrosis Factor Blocker class. 1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking INSTITUTO BUTANTAN - ADALIMUMABE. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use INSTITUTO BUTANTAN - ADALIMUMABE for extended periods without medical advice.